T1	Modifier 53 63	pathogenic
E1	Modifier:T1 Modifies:T56
T2	Or 64 66	or
E2	Or:T2 Arg:E1 Arg2:E3
T3	Assertion 67 73	likely
E3	Assertion:T3 Asserted:E56
A1	Assertion-Type-Value E3 possible
T4	Condition 85 99	PCDH19 variant
E4	Condition:T4 Name:T56
T5	Condition 124 132	seizures
E5	Condition:T5 Name:T57 Stability:T98
T6	Eq-Comparison 141 150	2 or more
E6	Eq-Comparison:T6 Value:T58 Operator:T59
T7	Condition 156 163	seizure
E7	Condition:T7 Name:T101
T8	Drug 164 175	medications
E8	Drug:T8 Minimum-Count:E6
T9	Condition 184 192	seizures
E9	Condition:T9 Name:T62 Minimum-Count:E60
T10	Temporal-Connection 193 197	over
E10	Temporal-Connection:T10 Arg:E9 Arg2:E11
A2	Temporal-Connection-Type-Value E10 during
T11	Eq-Comparison 200 214	12-week period
E11	Eq-Comparison:T11 Value:T102 Temporal-Unit:T103
T12	Condition 218 233	primary seizure
E12	Condition:T12 Name:T63 Temporality:E11
T13	Temporal-Connection 240 248	prior to
E13	Temporal-Connection:T13 Arg:E12 Arg2:E14
A3	Temporal-Connection-Type-Value E13 before
T14	Study 249 258	screening
E14	Study:T14 
T15	Procedure 300 310	treatments
E15	Procedure:T15 Stability:T65 Temporality:E61
T16	Procedure 312 334	Vagus nerve stimulator
E16	Procedure:T16 Name:T67 Stability:T107 Temporality:E21
T17	Observation 336 350	ketogenic diet
E17	Observation:T17 Name:T68 Stability:T107 Temporality:E21
T18	Or 352 355	and
E18	Or:T18 Arg:E17 Arg2:E19
T19	Observation 365 376	Atkins diet
E19	Observation:T19 Name:T69 Stability:T107 Temporality:E21
T21	Eq-Comparison 401 409	3 months
E21	Eq-Comparison:T21 Value:T70 Temporal-Unit:T71
T22	Temporal-Connection 410 418	prior to
E22	Temporal-Connection:T22 Arg:E21 Arg2:E23
A5	Temporal-Connection-Type-Value E22 before
T23	Study 419 428	screening
E23	Study:T23 
T24	Eq-Comparison 455 463	Previous
E24	Eq-Comparison:T24 Temporal-Period:T72
T25	Drug 476 486	ganaxolone
E25	Drug:T25 Name:T73 Temporality:E24
T26	Eq-Comparison 492 513	> 8 consecutive weeks
E26	Eq-Comparison:T26 Operator:T74 Value:T75 Temporal-Unit:T76
T27	Condition 517 524	seizure
E27	Condition:T27 Name:T77 Duration:E26
T28	Temporal-Connection 533 539	during
E28	Temporal-Connection:T28 Arg:E27 Arg2:E29
A6	Temporal-Connection-Type-Value E28 during
T29	Eq-Comparison 544 552	12 weeks
E29	Eq-Comparison:T29 Value:T78 Temporal-Unit:T79
T30	Temporal-Connection 553 561	prior to
E30	Temporal-Connection:T30 Arg:E29 Arg2:E31
A7	Temporal-Connection-Type-Value E30 before
T31	Study 562 571	screening
E31	Study:T31 
T33	Drug 595 610	strong inducers
E33	Drug:T33 Name:T81
T34	Or 611 613	or
E34	Or:T34 Arg:E33 Arg2:E35
T35	Drug 614 624	inhibitors
E35	Drug:T35 Name:T82
T37	Negation 642 645	not
E37	Negation:T37 Negates:E35 Negates2:E33
T38	Eq-Comparison 661 664	Use
E38	Eq-Comparison:T38 Temporal-Period:T84
T39	Drug 668 688	tetrahydrocannabinol
E39	Drug:T39 Name:T85 Temporality:E38
T40	Drug 690 693	THC
E40	Drug:T40 Name:T86
T41	Or 695 697	or
E41	Or:T41 Arg:E40 Arg2:E43
T42	Modifier 698 710	non-approved
E42	Modifier:T42 Modifies:T87
T43	Drug 711 722	cannabidiol
E43	Drug:T43 Name:T87
T44	Drug 724 727	CBD
E44	Drug:T44 Name:T110
T45	Negation 732 742	prohibited
E45	Negation:T45 Negates:E39 Negates2:E43
T46	Temporal-Connection 743 749	during
E46	Temporal-Connection:T46 Arg:E44 Arg2:E47
A8	Temporal-Connection-Type-Value E46 during
T47	Modifier 754 766	double-blind
E47	Modifier:T47 
T48	Other 794 799	other
E48	Other:T48 Is-Other:E50
T49	Study 800 815	investigational
E49	Study:T49 Study-Of:E50
T50	Drug 816 820	drug
E50	Drug:T50 Temporality:E51 Temporality2:E53
T51	Eq-Comparison 821 835	within 30 days
E51	Eq-Comparison:T51 Operator:T88 Value:T89 Temporal-Unit:T90
T52	Or 836 838	or
E52	Or:T52 Arg:E51 Arg2:E53
T54	Temporal-Connection 863 871	prior to
E54	Temporal-Connection:T54 Arg:E53 Arg2:E55
A9	Temporal-Connection-Type-Value E54 before
T55	Study 872 881	screening
E55	Study:T55 
T56	Condition-Name 85 99	PCDH19 variant
T57	Condition-Name 124 132	seizures
T58	Eq-Value 141 142	2
T59	Eq-Operator 143 150	or more
A10	Eq-Operator-Value T59 GTEQ
T61	Eq-Value 181 183	12
T62	Condition-Name 184 192	seizures
T63	Condition-Name 218 233	primary seizure
T64	Eq-Temporal-Period 264 266	On
A11	Eq-Temporal-Period-Value T64 present
T65	Stability 269 275	stable
A12	Stability-Value T65 stable
T67	Procedure-Name 312 334	Vagus nerve stimulator
T68	Observation-Name 336 350	ketogenic diet
T69	Observation-Name 365 376	Atkins diet
T70	Eq-Value 401 402	3
T71	Eq-Temporal-Unit 403 409	months
A13	Eq-Temporal-Unit-Value T71 month
T72	Eq-Temporal-Period 455 463	Previous
A14	Eq-Temporal-Period-Value T72 past
T73	Drug-Name 476 486	ganaxolone
T74	Eq-Operator 492 493	>
A15	Eq-Operator-Value T74 GT
T75	Eq-Value 494 495	8
T76	Eq-Temporal-Unit 508 513	weeks
A16	Eq-Temporal-Unit-Value T76 week
T77	Condition-Name 517 524	seizure
T78	Eq-Value 544 546	12
T79	Eq-Temporal-Unit 547 552	weeks
A17	Eq-Temporal-Unit-Value T79 week
T81	Drug-Name 595 610	strong inducers
T82	Drug-Name 614 624	inhibitors
T84	Eq-Temporal-Period 661 664	Use
A19	Eq-Temporal-Period-Value T84 present
T85	Drug-Name 668 688	tetrahydrocannabinol
T86	Drug-Name 690 693	THC
T87	Drug-Name 711 722	cannabidiol
T88	Eq-Operator 821 827	within
A20	Eq-Operator-Value T88 LTEQ
T89	Eq-Value 828 830	30
T90	Eq-Temporal-Unit 831 835	days
A21	Eq-Temporal-Unit-Value T90 day
T91	Eq-Operator 839 849	fewer than
A22	Eq-Operator-Value T91 LTEQ
T93	Eq-Value 850 851	5
T95	Modifier 74 84	pathogenic
E56	Modifier:T95 Modifies:T56
T96	Procedure 25 34	Molecular
E57	Procedure:T96 Name:T97
T97	Procedure-Name 25 34	Molecular
R1	Found-By Arg1:E4 Arg2:E57	
T98	Stability 116 123	control
A25	Stability-Value T98 stable
T99	Negation 105 112	Failure
E58	Negation:T99 Negates:T98
T100	And 133 140	despite
E59	And:T100 Arg:E5 Arg2:E8
T101	Condition-Name 156 163	seizure
R2	Treatment-For Arg1:E8 Arg2:E7	
T60	Eq-Comparison 181 183	12
E60	Eq-Comparison:T60 Value:T61
T102	Eq-Value 200 202	12
T103	Eq-Temporal-Unit 203 207	week
A26	Eq-Temporal-Unit-Value T103 week
T104	Eq-Comparison 264 266	On
E61	Eq-Comparison:T104 Temporal-Period:T64
T66	Condition 292 299	seizure
E62	Condition:T66 Name:T105
T105	Condition-Name 292 299	seizure
R3	Treatment-For Arg1:E15 Arg2:E62	
R4	Example-Of Arg1:E16 Arg2:E15	
R5	Example-Of Arg1:E17 Arg2:E15	
A27	Observation-Type-Value T68 social-habit
A28	Observation-Type-Value T69 social-habit
T106	Modifier 356 364	modified
E63	Modifier:T106 Modifies:T69
R6	Example-Of Arg1:E19 Arg2:E15	
T107	Stability 387 396	unchanged
A29	Stability-Value T107 stable
T20	Negation 525 532	freedom
E20	Negation:T20 Negates:E27
T32	Modifier 577 587	Concurrent
E32	Modifier:T32 Modifies:T81
T36	Modifier 628 634	CYP3A4
E36	Modifier:T36 Modifies:T82
T80	Modifier 635 636	5
E64	Modifier:T80 Modifies:T82
T83	Modifier 637 638	7
E65	Modifier:T83 Modifies:T82
T108	Or 634 635	/
E66	Or:T108 Arg:E36 Arg2:E64
T109	Or 636 637	/
E67	Or:T109 Arg:E64 Arg2:E65
R7	Example-Of Arg1:E40 Arg2:E39	
T110	Drug-Name 724 727	CBD
R8	Abbrev-Of Arg1:E44 Arg2:E43	
T53	Eq-Comparison 839 862	fewer than 5 half-lives
E53	Eq-Comparison:T53 Operator:T91 Value:T93 Unit:T92
T92	Eq-Unit 852 862	half-lives
